LifeSpan Vision Ventures Supports SENISCA In Advancing RNA Therapeutics For Ageing Diseases

NORWALK, Conn., has become the focal point for a significant development in the biotechnology sector, specifically within the realm of longevity and aging. LifeSpan Vision Ventures, an investment firm with a keen focus on longevity biotech investments, has announced its latest investment in SENISCA, a pioneering RNA therapeutics company spun out from the University of Exeter. This collaboration marks a significant step forward in the fight against age-related diseases through innovative RNA biology.

SENISCA's groundbreaking approach involves the reprogramming of aged 'senescent' cells, which are known to cease growth and secrete pro-inflammatory chemicals, contributing to various age-related diseases. The company has discovered a novel target within the cellular senescence response—RNA splicing dysregulation. This discovery opens up new avenues for pharmacological and skin health interventions, aiming to modify disease progression by targeting the root causes of cellular aging.

The investment from LifeSpan Vision Ventures will fuel SENISCA's ambitious plans for rapid evolution and the preclinical development of its senotherapeutic programmes. These programmes are designed to attenuate senescence through RNA splicing regulation, offering a promising new direction for treating age-related conditions.

Harry Robb, Analyst at LifeSpan Vision Ventures, expressed enthusiasm about joining forces with SENISCA. He highlighted the company's solid scientific foundation and commercially savvy management team as key factors in their decision to invest. "We are delighted to join SENISCA as new investors in this financing round," Robb stated, emphasizing the potential of SENISCA's senotherapeutic platform.

Dr. Sarah Cole, CEO of SENISCA, reciprocated this sentiment, welcoming LifeSpan Vision Ventures' investment and expertise. "The fund's deep understanding of science and technology and focus on collaboration synergizes with our mission to be a world-leader in developing novel senotherapeutics," Dr. Cole remarked. She looks forward to leveraging this partnership to unlock the full potential of SENISCA's technology.

About LifeSpan Vision Ventures

LifeSpan Vision Ventures stands at the forefront of investments in the aging and longevity sector. With a mission to accelerate the development of therapies that extend healthspan and improve life quality as individuals age, the firm is dedicated to addressing age-related challenges head-on. Through strategic investments and partnerships, LifeSpan Vision Ventures is committed to shaping a future where aging is associated with vitality and resilience.

About SENISCA

As an RNA therapeutics spinout from the University of Exeter, SENISCA is at the cutting edge of modulating RNA biology to combat age-related disease. With over 15 years of leading research underpinning its approach, SENISCA has identified key targets for intervention across a range of conditions affecting vital organs such as eyes, lungs, joints, and brain. The company's innovative platform technology holds promise for broad applicability in addressing multiple age-related diseases through novel senotherapeutics.

This partnership between LifeSpan Vision Ventures and SENISCA represents a significant milestone in the quest to develop effective treatments for age-related diseases. By harnessing advanced RNA biology and targeting cellular aging processes directly, this collaboration paves the way for transformative healthcare solutions that could significantly enhance quality of life for aging populations worldwide.